Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia
Interventions: peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Tibotec BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more

Conditions: HIV Infection, Hepatitis C Infection
Interventions: Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Hepatitis B
Interventions: Telbivudine (LdT), peginterferon alpha-2a; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more

Conditions: Hepatitis c
Interventions: pioglitazone (Actos), atorvastatin (Lipitor); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus Genotype-1
Interventions: TMC435, Pegylated interferon alpha-2a, Ribavirin; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Danoprevir, Pegasys, Ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: La Jolla, California • Sacramento, California • San Diego, California + 20 more

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 54
States / cities: Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 18
States / cities: San Diego, California • Ventura, California • Bradenton, Florida + 13 more

Conditions: Refractory Melanoma
Interventions: DOC1021, Tumor resection, pIFN (peginterferon alfa-2a); Biological · Procedure · Drug
Lead sponsor: Diakonos Oncology Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 8
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more

Conditions: Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions: Entecavir, Lamivudine, Pegylated Interferon Alfa-2A; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania

Conditions: Chronic Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Myeloproliferative Disorders
Interventions: IFN-alpha2a; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon/ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 18 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 18
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more

Conditions: Hepatitis B
Interventions: JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Beverly Hills, California • Baltimore, Maryland

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Nitazoxanide With Pegylated Interferon And Ribavirin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Infection
Interventions: Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Pegasys® in Patients With Myeloproliferative Diseases

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)